Evening Post Group (“EPG”), a family-owned operating group based in Charleston, South Carolina, is excited to announce the successful sale of EPI Health, LLC to Novan, Inc (NASDAQ: NOVN), a public specialty dermatology company based out of Durham, North Carolina.
EPI Health, first acquired by EPG in 2017, is a specialty pharmaceutical company focused on dermatology with various FDA approved medicines through several product acquisitions. EPI Health has become a leader in the space, operating a sales force of approximately 40 employees servicing dermatologists nationwide. The acquisition allows for EPI Health’s product portfolio to continue to address important medical issues alongside Novan’s innovative pipeline. EPG looks forward to watching the company’s next chapter with Novan.
EPG President and CEO Terry Hurley commented: “We are proud of what EPI Health has accomplished under EPG ownership. We see this acquisition as a great strategic fit for Novan and look forward to seeing the combined company take the next step in dermatology treatment.”
The transaction structure includes a closing purchase price of $27.5M consisting of $11M cash and $16.5 million as a 24-month seller note. Additional performance earnouts and specified milestones achieved by EPI Health’s products could increase the total consideration to approximately $50M.
Blank Rome LLP acted as legal advisor to EPG in connection with this transaction.
EPG is a family-owned operating group based in Charleston, South Carolina focused on acquiring and building exceptional businesses. Our approach is acquiring sustainable, differentiated businesses and providing the operational, strategic, and financial support to grow cash flows. EPG began in 1896 as a single newspaper and has evolved into an operator of businesses in various sectors through over 20 acquisitions in the past decade. EPG remains an active acquiror targeting middle market businesses across multiple industries.
Novan develops and markets therapeutic products for skin diseases. The company has a robust pipeline of products with the goal of delivering safe and effective therapies.
H.C. Wainwright & Co. acted as financial advisor and Smith Anderson acted as legal advisor to the Company in connection with this transaction.